Growth Metrics

Amneal Pharmaceuticals (AMRX) Accumulated Expenses (2018 - 2019)

Amneal Pharmaceuticals (AMRX) has 2 years of Accumulated Expenses data on record, last reported at $29.0 million in Q4 2019.

  • For Q4 2019, Accumulated Expenses fell 62.41% year-over-year to $29.0 million; the TTM value through Dec 2019 reached $29.0 million, down 62.41%, while the annual FY2019 figure was $29.0 million, 62.41% down from the prior year.
  • Accumulated Expenses reached $29.0 million in Q4 2019 per AMRX's latest filing, down from $77.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $77.1 million in Q4 2018 and bottomed at $29.0 million in Q4 2019.